SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Merck Research Laboratories in South San Francisco, California
RSV
Merck Wins FDA Nod for RSV Antibody, Tees Up Challenge to Sanofi, AstraZeneca
Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the third quarter.
June 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Planning strategy and ways to achieve business goals, searching for new opportunities for high results, direction of career development, the path to great success, man changes direction on signpost.
Policy
FDA Brings Back Previously Disbanded Generic Drug Policy Panel
The reinstatement of the generic drug policy office is the latest reversal of course for Robert F. Kennedy Jr.'s HHS, which also recently rehired FDA staff responsible for making travel arrangements and those involved in user fee program negotiations.
June 10, 2025
 · 
2 min read
 · 
Tristan Manalac
vaccines
In ‘Bold’ Move, RFK Jr. ‘Retires’ All 17 Members of CDC’s Vaccine Committee
Two weeks of upheaval at the CDC culminated Monday in the complete reconstitution of the CDC’s Advisory Committee on Immunization Practices as HHS Secretary Robert F. Kennedy Jr. pens op-ed criticizing “conflicts of interest” he says exist on the current committee.
June 9, 2025
 · 
2 min read
 · 
Heather McKenzie
Contemporary art collage. Conceptual design with young woman, motivated employee running forward to reach goal, professional success. Concept of business, career development, achievement
Neurodegenerative disease
Avidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle Strength
Avidity has been given the go-ahead by the FDA to request accelerated approval of delpacibart braxlosiran—potentially the first disease-modifying treatment for facioscapulohumeral muscular dystrophy—with an application in the second half of 2026.
June 9, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Unvaccinated And vaccinated people as anti-vaxxer or individuals that oppose taking the vaccine with 3D illustration elements.
Vaccines
ACIP Members Receive Termination Notices as Fears Mount Over RFK Jr.’s Vaccine Machinations
The loss of special government employee status for four members of the CDC’s Advisory Committee on Immunization Practices follows the resignation of ACIP co-lead Lakshmi Panagiotakopoulos, who left in protest of a controversial change in COVID-19 recommendations for healthy children and pregnant women.
June 9, 2025
 · 
2 min read
 · 
Heather McKenzie
Man pushing against giant dollar bill, symbolizing burden of financial challenges amidst inflation and economic pressure. Conceptual creative design. Concept of inflation, finances
Duchenne muscular dystrophy
Keros To Return $375M to Investors After Shareholder Activism, Safety Signal
After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts called “a positive step forward.”
June 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Cardiovascular disease
Merck Moves Forward in Bid To Bring First Oral PCSK9 Inhibitor to Market
Merck’s enlicitide decanoate significantly lowered low-density lipoprotein cholesterol in two Phase III trials, unlocking what BMO Capital Markets called a “multi-billion dollar opportunity” for the pharma.
June 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Weight loss
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Days
In what Guggenheim Partners called one of Metsera’s “critical program milestones” this year, its ultra-long-acting amylin injection MET-233i showed promising weight-loss after a little more than a month of treatment.
June 9, 2025
 · 
3 min read
 · 
Tristan Manalac
World kidney day. Human hands holding healthy kidney shape made from paper on light blue background.
Rare diseases
Apellis, Sobi See Potential ‘Best-in-Class’ Efficacy for Empaveli in Rare Kidney Diseases
Empaveli reduced proteinuria by 68% versus placebo in glomerulopathy and glomerulonephritis, an effect that was sustained through one year of follow-up.
June 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS